Article

New Developments in Epilepsy Research

Author(s):

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research.

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research in all areas: genetics; variety of treatment modalities including epilepsy surgery and pharmacologic treatment; in our understanding of the pathogenic mechanisms associated with epilepsy.

“Neuro-imaging in epilepsy has transformed our way of evaluating patients both as far as evaluation for epilepsy surgery as well as understanding cognitive changes associated to those disorders. I particularly have been very interested in the development of a new surgical technique known as laser ablation that is MRI- guided as is used to treat people with temporal epilepsy or epilepsy that is associated with focal dysplasias.”

This surgical approach is not as invasive as a resection, and allows them to offer this treatment to patients that in the past were reluctant to consider surgical strategies. So far, this technique has been used in a greater number of epilepsy centers in the country and has been considered to be used outside of the US with some promise.

According to Kanner, the results obviously are limited being that they only have 1 or 2 years of follow up data, but so far that data looks quite promising. If these results are maintained for the next 5-10 years, then this could be a minimally invasive surgical approach that can replace some of the temporal resections that are typically done in epilepsy centers.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.